Synpromics have been awarded Best Emerging UK Synthetic Biotech Company at the 2017 OBN Awards for enabling safer, more effective cell and gene medicines.
Synpromics will provide key muscle-selective promoter candidates for the development of new treatment options for Duchenne muscular dystrophy (DMD).
The new custom-built centre based at the University of Edinburgh’s allows us to meet increasing global demand for its cutting-edge gene control technology.
Synpromics, the leading synthetic promoter and gene control company, is pleased to announce that it has completed a financing round of £5.2M.
Edinburgh, UK, 16th March 2017 / Synpromics Ltd, the leading synthetic promoter and gene control company, is pleased to announce it has been granted a key patent (E